Skip to main content

Table 1 Demographic and clinicopathologic characteristics of 308 subjects comprising ELISA study cohort and 193 subjects comprising IHC study cohort

From: Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer

  ELISA Cohort IHC Cohort
BCa (%) n = 102 Controls (%) n = 206 BCa (%) n = 185 Controls (%) n = 8
Median Age (range, y) 69 (20–93) 56 (18–89) 73 (30–94) 26 (21–43)
Male: Female ratio 84 : 18 152 : 54 143 : 42 4 : 4
Race     
  White 91 (89%) 135 (66%) 156 (84%) N/A
  African American 5 (5%) 20 (10%) 8 (4%) N/A
  Other 6 (6%) 51 (24%) 19 (12%) N/A
Positive FISH 40 / 74 (54%) 2/22 (9%) N/A N/A
Suspicious/positive cytology 37 / 94 (39%) 2/22 (9%) N/A N/A
Median follow-up (months) 14 4 18 N/A
Clinical stage     
  Tis 6 (6%)   17 (9%)  
  Ta 41 (40%)   45 (24%)  
  T1 14 (14%)   63 (34%)  
  ≥T2 41 (40%)   60 (33%)  
Tumor grade     
  Low 38 (37%)   27 (15%)  
  High 64 (63%)   158 (85%)  
Median tumor size (cm) 3.0   3.0  
  1. IHC immunohistochemistry, BCa bladder cancer, N/A not available.